ESR1 and breast cancer: Indeed, although Tam extends the overall survival of approximately 85% of ERα-positive BC patients for as long as 5 years after diagnosis [32,33], prolonged Tam treatment causes in a large proportion of patients the development of cells resistant to this anti-ERα drug through different mechanisms [30,33,34,35,36,37,38,39,40,41].